Recent Quotes (30 days)

You have no recent quotes
chg | %

Vistagen Therapeutics Inc  

(Public, NASDAQ:VTGN)   Watch this stock  
Find more results for VTGN
1.06
-0.07 (-6.17%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.99 - 1.12
52 week 0.99 - 4.20
Open 1.12
Vol / Avg. 112,962.00/48,293.00
Mkt cap 11.40M
P/E     -
Div/yield     -
EPS -1.36
Shares 10.75M
Beta -1.13
Inst. own 18%
Nov 13, 2017
Q2 2018 VistaGen Therapeutics Inc Earnings Release (Estimated) Add to calendar
Aug 14, 2017
Q1 2018 VistaGen Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin - -820.44%
Operating margin - -819.88%
EBITD margin - -815.49%
Return on average assets -295.53% -436.22%
Return on average equity -2015602.00% -
Employees 10 -
CDP Score - -

Address

343 Allerton Ave
SOUTH SAN FRANCISCO, CA 94080-4816
United States - Map
+1-650-5773600 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.

Officers and directors

H Ralph Snodgrass Ph.D. President, Chief Scientific Officer, Director
Age: 65
Bio & Compensation  - Reuters
Shawn K. Singh J.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jerrold D. Dotson CPA Chief Financial Officer, Vice President, Company Secretary
Age: 61
Bio & Compensation  - Reuters
Mark A. McPartland Vice President - Corporate Development and Investor Relations
Age: 49
Bio & Compensation  - Reuters
Mark A. Smith M.D. Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Jerry B Gin Ph.D. Director
Bio & Compensation  - Reuters
Jon S. Saxe J.D. Independent Director
Age: 80
Bio & Compensation  - Reuters
Brian J. Underdown Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters